Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:albiglutide
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
|
| gptkbp:ATCCode |
A10BX10
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eperzan
|
| gptkbp:indication |
glycemic control in adults with type 2 diabetes
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
GLP-1 receptor agonist
|
| gptkbp:otherName |
gptkb:Tanzeum
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:withdrawn |
2018
|
| gptkbp:bfsParent |
gptkb:albiglutide
gptkb:LG_Life_Sciences |
| gptkbp:bfsLayer |
7
|